X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Emend-Generic(fosaprepitant) is a NK1 receptor antagonist, indicated in adults and pediatric patients aged 6 months & older along with other antiemetic agents, for the prevention of acute & delayed nausea & vomiting associated with initial & repeat courses of chemotherapy.
Lead Product(s): Fosaprepitant
Therapeutic Area: Gastroenterology Product Name: Emend-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Details:
Under the agreement, CTTQ will manufacture Fosaprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist, for Injection, the therapeutic generic equivalent of Emend, and will be sold under the Techdow USA Label.
Lead Product(s): Fosaprepitant
Therapeutic Area: Gastroenterology Product Name: Emend-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Techdow USA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 22, 2023
Details:
Fosaprepitant for Injection, 150 mg Single-Dose Vial, is the generic equivalent of Emend® for Injection, 150 mg Single-Dose Vial, of Merck indicated for adults in combination with other antiemetic agents.
Lead Product(s): Fosaprepitant
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
